论文部分内容阅读
目的分析米非司酮对子宫肌瘤雌激素受体(ER)、孕激素受体(PR)的影响及其临床应用价值。方法 60例子宫肌瘤合并贫血患者,随机分为研究组和对照组,各30例。研究组予以米非司酮治疗,对照组则不用药。切除肌瘤后立即置于甲醛溶液固定24 h取材,通过S-P免疫组化法检测两组组织上ER、PR,分析对比两组组织受体积分表达情况。结果治疗后,研究组肌瘤体积[(211.23±87.12)cm~3VS(159.21±58.06)cm~3]及子宫体积[(452.38±158.46)cm~3 VS(368.42±154.31)cm~3]均较治疗前减小;研究组子宫肌瘤组织中ER、PR积分均明显低于对照组[(0.43±0.18)分VS(0.78±0.21)分,(0.41±0.12)分VS(0.69±0.13)分],差异均有统计学意义(P<0.05)。用药后,研究组血红蛋白(HGB)由(100.2±4.9)g/L明显增加至(110.8±7.6)g/L。结论小剂量米非司酮可有效降低子宫肌瘤的ER、PR含量,减小肌瘤体积,是治疗子宫肌瘤的有效方法。
Objective To analyze the effect of mifepristone on estrogen receptor (ER) and progesterone receptor (PR) in uterine fibroids and its clinical value. Methods 60 cases of uterine fibroids with anemia were randomly divided into study group and control group, 30 cases each. The study group to mifepristone treatment, the control group did not medication. The fibroids were removed and fixed in formalin solution for 24 h. The expressions of ER and PR in the two groups were detected by S-P immunohistochemistry. Results After treatment, the volume of fibroids in the study group was significantly higher than that in the control group [(211.23 ± 87.12) cm ~ 3VS (159.21 ± 58.06) cm ~ 3] and uterine volume [(452.38 ± 158.46) cm ~ 3 VS [368.42 ± 154.31] cm ~ (0.43 ± 0.18) points VS (0.78 ± 0.21) points, (0.41 ± 0.12) points VS (0.69 ± 0.13) points in the study group were significantly lower than those in the control group Points], the differences were statistically significant (P <0.05). After treatment, the study group hemoglobin (HGB) increased significantly from (100.2 ± 4.9) g / L to (110.8 ± 7.6) g / L. Conclusion Small doses of mifepristone can effectively reduce the ER, PR content of uterine fibroids and reduce the size of fibroids, which is an effective method for the treatment of uterine fibroids.